{"id":"placebo-matched-to-vx-661-ivacaftor","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL2010601","moleculeType":"Small molecule","molecularWeight":"392.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector that helps misfolded CFTR protein fold correctly and traffic to the cell surface. Ivacaftor is a CFTR potentiator that increases the open probability of the CFTR channel, allowing chloride ions to flow through. Together, they work synergistically to restore CFTR function in patients with specific CFTR mutations.","oneSentence":"This is a placebo control arm in a clinical trial comparing VX-661 (a CFTR corrector) combined with ivacaftor (a CFTR potentiator) against placebo in cystic fibrosis patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:48.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulators"}]},"trialDetails":[{"nctId":"NCT02070744","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-03","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT04006873","phase":"PHASE2","title":"Gut Imaging for Function & Transit in Cystic Fibrosis Study 2","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2019-09-03","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT03912233","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-04-30","conditions":"Cystic Fibrosis","enrollment":87},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT03768089","phase":"PHASE1, PHASE2","title":"Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-20","conditions":"Cystic Fibrosis","enrollment":115},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT02508207","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":34},{"nctId":"NCT03224351","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-08-08","conditions":"Cystic Fibrosis","enrollment":124},{"nctId":"NCT02951195","phase":"PHASE2","title":"A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":80},{"nctId":"NCT02951182","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-10","conditions":"Cystic Fibrosis","enrollment":74},{"nctId":"NCT03525444","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-06-15","conditions":"Cystic Fibrosis","enrollment":405},{"nctId":"NCT03447249","phase":"PHASE3","title":"A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-07","conditions":"Cystic Fibrosis","enrollment":385},{"nctId":"NCT03559062","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-05-17","conditions":"Cystic Fibrosis","enrollment":67},{"nctId":"NCT03525548","phase":"PHASE3","title":"A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-03","conditions":"Cystic Fibrosis","enrollment":113},{"nctId":"NCT02730208","phase":"PHASE2","title":"A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-09","conditions":"Cystic Fibrosis","enrollment":41},{"nctId":"NCT03460990","phase":"PHASE3","title":"A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-05-01","conditions":"Cystic Fibrosis","enrollment":116},{"nctId":"NCT03150719","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-05-24","conditions":"Cystic Fibrosis","enrollment":98},{"nctId":"NCT02392234","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-03","conditions":"Cystic Fibrosis","enrollment":248},{"nctId":"NCT02347657","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-01","conditions":"Cystic Fibrosis","enrollment":510},{"nctId":"NCT02516410","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":168},{"nctId":"NCT01531673","phase":"PHASE2","title":"Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Cystic Fibrosis","enrollment":194},{"nctId":"NCT03486236","phase":"PHASE1","title":"A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-07-20","conditions":"Cystic Fibrosis","enrollment":16},{"nctId":"NCT03029455","phase":"PHASE1","title":"A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-11","conditions":"Cystic Fibrosis","enrollment":163}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matched to VX-661/ ivacaftor","genericName":"Placebo matched to VX-661/ ivacaftor","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm in a clinical trial comparing VX-661 (a CFTR corrector) combined with ivacaftor (a CFTR potentiator) against placebo in cystic fibrosis patients. Used for Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulators.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}